Introduction

The Orphan Drug Act of 1983 is the rare statute whose mechanism can be stated in one sentence and whose consequences took three decades to map. Congress diagnosed a market failure, not a scientific one: developing a drug cost roughly the same whether the patient population numbered a million people or a thousand, so conditions affecting small populations attracted almost no commercial development. The law answered without picking diseases or funding development directly. It granted seven years of market exclusivity that ran independently of the patent system, a tax credit for qualifying clinical testing, a waiver of application fees, research grants, and written agency guidance on trial design, with every benefit flowing from a single orphan designation.

The statute worked on the measure that mattered. In the decade before its passage, roughly ten drugs for rare conditions reached American patients. Through the end of 2017, the Food and Drug Administration had granted nearly 4,500 orphan designations and approved more than 650 orphan drugs for conditions that previously had no treatments. Regulators in Europe and Japan built comparable regimes on the American template, and the statute is widely described as the model for orphan drug policy worldwide.

The same design choice produced the gaming that government auditors and academic researchers documented. Because exclusivity attaches to the designated indication rather than to the molecule, a sponsor can define a narrow slice of a common condition, claim the incentives, and then sell into a much larger market. Investigations found that roughly a third of orphan approvals were for repurposed mass-market drugs or for drugs carrying multiple orphan approvals, and orphan-designated products command among the highest prices in medicine.

This profile carries the whole arc in one article because the statute has no specialist siblings: the congressional findings that named the arithmetic, the prime-time television episode credited with generating the public pressure that passed the bill, the numerical definition that made eligibility administrable, the five incentives, the measured results, and the subdivision critique. The efficacy requirements imposed by the Kefauver-Harris Amendments of 1962 had raised the price of proof for every new medicine; the Orphan Drug Act of 1983 was the statute that priced the proof back down for the smallest patient populations.

The Problem

Before the Orphan Drug Act became law in 1983, the American drug industry had a straightforward reason for ignoring the diseases that affected the fewest people. The reason was arithmetic. Bringing a medicine from the laboratory to the pharmacy shelf cost roughly the same amount whether that medicine would eventually treat a million people or a thousand, while the revenue it could earn depended almost entirely on how many patients would buy it. When the patient count was small, the numbers did not work, and the industry put its money elsewhere. Congress wrote that diagnosis directly into the statute, in findings that described a company developing such a medicine as facing sales that would be “relatively small … in comparison to the cost of developing the drug” and therefore likely to “incur a financial loss.” Those findings, preserved on the Food and Drug Administration’s own page of Orphan Drug Act excerpts from Public Law 97-414, are the clearest short statement of the problem the law was built to fix. It was a market failure, not a scientific one.

Why would a drug company leave a disease without a treatment?

Because the money spent to develop a medicine has to be earned back from the people who take it. When only a few thousand people have a condition, even a high price per patient cannot reliably cover the cost of research and clinical testing, so companies direct their research budgets toward conditions whose patient populations are large enough to make the investment pay.

Most of the cost of a new drug is fixed. The preclinical research, the toxicology work, the staged clinical trials in volunteers and patients, the statistical analysis, and the preparation of a new drug application for the Food and Drug Administration cost what they cost regardless of how many people eventually take the finished product. The patient population is therefore not just a measure of the public health need; it is the ceiling on the revenue available to recover everything spent before approval. The congressional findings put this bluntly: with so few individuals affected by any one rare disease, a pharmaceutical company that developed a drug for such a condition could reasonably expect relatively small sales compared with the cost of development and consequently a financial loss.

A simple division shows how tight the ceiling was. An economist’s synthesis of the era’s cost studies, discussed below, put the out-of-pocket cost of bringing one new drug through approval in the 1970 to early 1980s period at 65.7 million dollars in year 2000 purchasing power. Spread across a patient population of, say, five thousand people, that development cost alone amounts to more than thirteen thousand dollars per patient, before manufacturing, distribution, marketing, or any return on the investment is counted. Spread across five million people, the same cost amounts to about thirteen dollars per patient. The medicine in the two cases is identical in every scientific respect; only the arithmetic differs. This is why the industry’s research portfolios of the era tilted toward conditions such as heart disease, arthritis, and asthma, where the patient base was counted in the tens of millions, and why compounds aimed at small populations were routinely set aside even when they appeared to work.

The industry’s own figures reinforced the logic. A 2007 industry profile published by the Pharmaceutical Research and Manufacturers of America noted that only three of ten marketed drugs ever produce revenues that match or exceed their research and development costs. The business model therefore depended on a few large-selling medicines carrying the cost of many projects that never paid for themselves. A drug for a rare condition could never join that side of the ledger, because the patient count capped its upside from the start. In that environment, abandoning a rare-disease compound was not a judgment on the science. It was a judgment on the math.

The rationing happened project by project, inside research budgets that were finite in any given year. Every dollar committed to a rare condition was a dollar not spent on a common one, and the comparison was unforgiving. A research manager weighing two candidates with equal scientific promise and equal development cost had to weigh, on the other side, a revenue ceiling that might differ by a factor of a thousand. With only three in ten marketed drugs ever earning back their costs, every project carried the risk of total loss, and the rational way to bear that risk was to pair it with the largest possible upside. Small patient populations offered the smallest possible upside. The result was not a conspiracy against the rare; it was the ordinary, repeated outcome of portfolio decisions made under uncertainty, and it left rare conditions systematically unfunded.

What did developing a new drug cost in the years before the statute?

Estimates varied with method, but every serious estimate rose steeply over time. In a 2011 working paper from Harvard’s Kennedy School, the economist F. M. Scherer converted the classic studies to a common base of year 2000 dollars: about 5.4 million dollars per approved drug in the late 1950s.

The climb continued: about 40.2 million in the late 1960s, about 65.7 million for the 1970 to early 1980s cohort, and about 282 million for the 1983 to late 1990s cohort.

These figures are averages per successfully approved molecule, and they fold in three things that made drug development expensive even apart from any particular compound. The first is failure: only a fraction of the compounds that enter human testing ever win approval, so the cost of the failures is prorated onto the successes. The second is time: the same industry profile that reported the revenue figures above put the development of a new drug at ten to fifteen years, and money tied up for that long carries a substantial opportunity cost. The third is that preclinical and clinical work kept getting more elaborate, with larger and longer trials in each successive era. An Office of Health Economics review published in 2012, covering several decades of estimates, found the same upward slope, placing the cost per new medicine in the 1970s at roughly 125 million pounds (about 199 million dollars) and in the 2000s at roughly 1.2 billion pounds (about 1.9 billion dollars), both in 2011 prices. Researchers disagreed about the exact level, but not about the direction. And the direction explained why the problem was getting worse rather than holding steady: the cost per approved drug roughly doubled between each successive cohort in Scherer’s series, so the set of patient populations large enough to carry that cost kept shrinking. Conditions at the small end of the distribution dropped out of commercial consideration first, and the boundary of commercial viability kept moving against them.

The direction mattered because none of it scaled down for small markets. A clinical program of a given size cost the same whether it supported an application for a medicine used by millions or one used by a few thousand. As the average cost per approval climbed from the tens of millions into the hundreds of millions, the number of patient populations that could plausibly carry that cost kept shrinking, and the conditions at the small end of the distribution dropped out of commercial consideration first.

How did the efficacy requirement raise the price of proof?

The Kefauver-Harris Amendments of 1962 required manufacturers to prove not only that a medicine was safe but that it was effective, through adequate and well-controlled clinical investigations. Generating that proof demanded larger trials, more data, and years of additional work, and the expense of the proof did not shrink when the target population was small.

Before 1962, American drug law required a showing of safety; the amendments, enacted after the thalidomide disaster, added an efficacy standard that the Food and Drug Administration enforced through evidentiary rules for new drug applications. Scherer attributed the largest jump in the cost series, the gap between the late 1960s estimates and everything after, to this change: after 1962, he wrote, “constrained by new and tougher legislation,” the agency “enforced much more stringent rules for the evidence it would accept before approving new drug applications.” The trials grew, the paperwork grew, and the cost of producing an approval grew with them.

The consequence was visible in the public debate of the 1970s and early 1980s, when patients’ groups, academic scientists, and industry representatives alike pointed to the 1962 amendments as the source of what they called the drug lag: lengthier, costlier approval procedures that delayed new medicines relative to other countries. Whether the lag was real or exaggerated was disputed, but the direction of the cost pressure was not. It is also worth noting what did not contribute to the cost. The user fees that later financed part of the agency’s review work did not exist yet; they arrived with the Prescription Drug User Fee Act of 1992. In the years before the Orphan Drug Act, the regulatory cost of approval was almost entirely the cost of running the trials and assembling the evidence, not the cost of paying the regulator. That evidentiary cost was the same for a medicine with a thousand patients as for one with a million.

The efficacy standard also interacted badly with small populations in a second way. Proving effectiveness to a regulator requires recruiting enough patients to make a trial statistically persuasive, and when a disease affects only a few thousand people nationwide, scattered across the country, recruitment itself becomes slow and expensive. A review of orphan drug development in the National Institutes of Health’s public archive notes that rare-disease trials face exactly these difficulties: small, geographically dispersed patient pools, disease mechanisms that are poorly understood, and trial designs that must be built almost from scratch. The result was a double squeeze. The medicines whose revenue ceiling was the lowest were also the medicines for which generating the required proof was the most expensive per patient enrolled.

How many rare-disease drugs reached the market in the decade before the statute?

About ten. The AMA Journal of Ethics reported that only ten orphan drugs were available between 1973 and 1983, and the FDA’s Office of Orphan Products Development gave the same count for the decade before the law passed, through senior regulatory counsel Aaron Friedman in a 2017 interview with Kaiser Health News.

The all-time count was not much larger. A 2013 retrospective in Pharmaceutical Executive put the total number of drugs approved for rare diseases before the law at thirty-eight, and a 2003 congressional concurrent resolution stated that “less than 40 therapies existed to treat orphan diseases” before 1983. A separate paper in the National Institutes of Health’s public archive estimated that fifty-eight new drugs approved between 1967 and 1983 “could have qualified” for orphan status, a higher number because it applies the definition retroactively to a longer window. The differences among the counts reflect different windows and different ways of deciding which old approvals would count as rare-disease drugs under a definition written later. Whichever count is used, the output of the industry for rare conditions in the decade before the statute was tiny.

The burden it was measured against was not tiny. The 2003 congressional resolution counted six thousand known rare diseases and conditions affecting approximately twenty-five million Americans. Set against that, ten approvals in ten years meant that nearly every rare condition faced the same prospect: no commercial development program, no pipeline of candidate compounds, and no expectation that one would appear. The statute’s own findings said exactly this, noting that “adequate drugs for many of such diseases and conditions have not been developed.” The decade before the law was not a period in which rare diseases went untreated because their biology was unusually mysterious. It was a period in which the development system, left to its own economics, did not develop treatments for them.

Which conditions went without any treatment pipeline?

The conditions Congress named in the statute’s own findings: Huntington’s disease, myoclonus, amyotrophic lateral sclerosis (ALS, also called Lou Gehrig’s disease), Tourette syndrome, and muscular dystrophy. The findings stated that these diseases and conditions affected such small numbers of people in the United States that they were considered rare.

Adequate drugs for many of them had not been developed.

The Tourette syndrome case shows how the market failure worked on a single compound. In the late 1970s, a physician at what was then the Mount Sinai School of Medicine in New York, Arthur K. Shapiro, ran a small clinical trial of pimozide, a compound under investigation as a treatment for schizophrenia, for use in children with Tourette syndrome. The treatment worked: symptoms were substantially reduced without the sedation caused by the other medicines that had been tried. But pimozide then failed in its schizophrenia trials, and its manufacturer, McNeil Laboratories, pulled out of the treatment’s development because the larger and more profitable indication had not panned out. The Tourette syndrome study was halted, and the medicine became unavailable in the United States. As The Scientist reported in a 2008 retrospective, the compound’s promise for Tourette syndrome did not warrant further investment, because the condition affected too few people to justify the cost. A working medicine, with demonstrated effect in patients, was abandoned for arithmetic.

The pipeline problem was therefore two-sided. Few compounds were ever developed specifically for rare conditions, and compounds that were developed for common conditions were not carried through for rare ones when the larger indication failed. What remained for patients was mostly borrowed: medicines approved for other purposes, prescribed for symptoms they were never designed to treat, with partial benefit and heavy side effects. The statute’s finding used the careful word “adequate” when it said that adequate drugs for many of these diseases and conditions had not been developed, and the pimozide case shows what adequate meant in practice. A medicine that worked well for Tourette syndrome existed, had been tested in children, and was then withdrawn from development because it had failed at something else. For the patients it would have served, the pipeline was not merely thin. It was empty.

The pattern repeated across the conditions Congress had listed. Huntington’s disease, a fatal inherited neurodegenerative disorder, had no disease-modifying treatment and no commercial development program aimed at one. Myoclonus, amyotrophic lateral sclerosis, and the muscular dystrophies likewise sat outside the industry’s research portfolios. These were not obscure curiosities; ALS and muscular dystrophy were well known to the public, and Huntington’s disease had a recognized patient community. What they shared was small patient populations, and in the economics of drug development before 1983, that was enough to keep every one of them out of the pipeline.

Congress stated the diagnosis in the law’s own findings, and the findings read as a description of a broken market rather than of a scientific frontier. A company developing a medicine for a rare disease could reasonably expect small sales compared with the cost of development and consequently a financial loss. Some promising drugs would not be developed at all unless federal law changed to reduce the costs and supply financial inducements. And it was in the public interest to make those changes. The original definition of a rare disease in the 1983 law was itself written in these economic terms: a condition for which there was no reasonable expectation that development costs would be recovered from domestic sales, with the numerical population threshold added by amendment the following year. The problem, as Congress framed it, was never that the medicines were impossible. It was that the market, left alone, would not pay for them.

Origins

The Orphan Drug Act began as a response to a simple economic arithmetic that no amount of good intentions had disturbed. Developing a medicine costs roughly the same whether the eventual patient population numbers in the millions or in the hundreds, so conditions that affected small populations drew almost no commercial interest. These abandoned medicines came to be called orphan drugs, a name that captured the way patients had been left behind by the medical and scientific community, in the anniversary phrasing of the National Organization for Rare Disorders, known as NORD. In the decade before 1983, industry brought only ten new treatments to market for diseases that fall within the rare-disease definition, according to NORD. Waxman recalled in the Congressional Record that before 1980, drug companies did virtually no research to find cures for rare diseases, because the populations were so small that no adequate return on investment appeared possible. Patients and their families lived with the consequences of that arithmetic one diagnosis at a time, and the statute that changed it grew out of their decision to stop confronting it alone.

The Families Who Started Organizing Together

Through the late 1970s, leaders of patient organizations built around individual rare conditions began to notice that their separate struggles shared the same shape. NORD’s own history records that these leaders realized there were problems their patients and families had in common, difficulties that belonged to everyone with a rare disease rather than to any one diagnosis. Parents of children with Tourette syndrome found themselves comparing notes with families touched by Huntington disease, cystic fibrosis, and muscular dystrophy, and the comparisons kept landing in the same place: no treatments, no research pipeline, and no commercial reason for either to exist.

The central figure among the early organizers was Abbey Meyers, a mother whose family lived with Tourette syndrome and who became, in NORD’s words, the primary patient advocate for what became the Orphan Drug Act. She and other advocates, among them Ruby Horansky, began linking disease-specific groups into an informal coalition that lobbied Washington for legislative action. Waxman, who championed the bill in the House, later wrote in his memoir that the first congressional hearing on the issue, held in June 1980, drew a sparse crowd and little public notice, with only a Los Angeles Times reporter present to cover it. That reporter attended partly because the hearing’s central witness, a young Tourette syndrome patient, was a local resident, and the story that reporter wrote became the seed of everything that followed. The advocates had the facts on their side and almost no audience.

What they lacked in visibility they made up for in persistence. The ad hoc coalition of patient organization leaders learned the mechanics of congressional advocacy from scratch, meeting with members and staff, arranging testimony, and teaching themselves how to translate family desperation into legislative language. Applied Clinical Trials Online later described how the coalition taught itself to be advocates for the patients and families it represented. The work bore the shape of a movement before it had a name: the coalition gave itself the name National Organization for Rare Disorders only after the statute passed, formally incorporating as NORD on May 4, 1983, four months after President Ronald Reagan signed the bill. At its founding the new organization already brought together forty to fifty disease-specific groups under one umbrella, according to MDedge’s anniversary account, and its stated purpose was to provide advocacy, education, research, and patient and family services for Americans affected by rare diseases. The organizing came first; the institution followed the law it had helped create.

The Night Prime Time Took Up the Cause

The hearing that almost no one attended in June 1980 produced an unexpected consequence. The Los Angeles Times reporter who had covered it wrote a small story about the orphan drug problem, and that story found its way to Maurice Klugman, a Hollywood writer and producer who at the time was himself living with a rare form of cancer. NORD’s history traces the chain directly: a small story in the Los Angeles Times led to an episode of a popular television show, Quincy, M.E., and after the broadcast, letters began to arrive from people across the country who had rare diseases and had believed they were alone in their struggles.

Maurice Klugman decided to write an episode of the NBC medical drama, which starred his brother Jack Klugman as a crusading medical examiner. Working with writer Sam Egan, he produced “Seldom Silent, Never Heard,” in which the death of a teenager with Tourette syndrome draws Quincy into the question of why no medicines exist for such conditions. Maurice Klugman served as a producer on the show, and his brother’s own account of the series, given to the Chicago Tribune in a 1993 interview reported by NORD, was that the program appealed to him partly because it allowed him to do important shows on important topics rather than simply entertain. Episode listings record that the installment aired on March 4, 1981, as the fourteenth episode of the show’s sixth season, and the plot centered on the refusal of drug companies to develop treatments for disorders too rare to reward the investment. The message was pointed and political: a prime-time audience watched the fictional coroner aim his anger at the economics that left small patient populations without medicine.

The response exceeded anything the patient advocates had managed on their own. Viewers who had never heard the term orphan drug wrote to the show, to their representatives, and to each other, and the letters kept arriving. For the first time, the scattered families who had been organizing in the late 1970s could see evidence that they were not scattered at all, but numerous and connected. The broadcast converted a policy problem that had drawn a sparse hearing room into a subject of national conversation, and it did so without any advocate having to explain the legislative mechanics. The episode did what years of meetings had not: it gave the public a story to carry into the political arena.

The Actor in the Hearing Room

Television’s involvement did not end with the broadcast. Representative Henry Waxman of California, the Democrat who chaired the House Subcommittee on Health and the Environment, saw the publicity the episode generated and moved to capture its momentum. Waxman invited Jack Klugman to Washington to testify about the orphan drug problem before the subcommittee, and Klugman accepted. The New York Times covered the hearing under the headline “HOUSE TOLD OF NEED FOR ‘ORPHAN DRUGS’” in its edition of March 10, 1981, marking the moment a prime-time star carried the issue from a studio lot into a congressional hearing room.

Klugman made no pretense of appearing as a scientific authority. Reporting on the testimony notes that he told the subcommittee he came not as an expert but as a celebrity, and he asked the members how many cries would have to go unheard before the country acted. The frankness worked in his favor. In an era when celebrity engagement with Congress was still unusual, his presence drew cameras and coverage to a subject that had previously attracted one reporter, and the coverage carried the patient advocates’ arguments into newspapers and living rooms far beyond the hearing room. The legislative history that followed would credit the broadcast and the testimony with producing the public pressure that the advocates’ careful lobbying had not yet achieved on its own.

The Bill’s Path Through the Committees

The legislative vehicle for the cause was H.R. 5238, introduced in the House on December 15, 1981, by Waxman, who represented California’s 24th district and chaired the health subcommittee that had heard Klugman’s testimony. An earlier version of orphan drug legislation had been introduced by former Representative Elizabeth Holtzman, but the Waxman bill became the measure around which the House organized its effort. Congress.gov records the bill’s committee path: the House Committee on Energy and Commerce and the House Committee on Ways and Means took up the measure, and on the Senate side the bill went to the Committee on Labor and Human Resources. The Ways and Means referral reflected the bill’s tax provisions, which the House tax-writing committee had to approve before the measure could move.

In the Senate, the companion effort drew bipartisan leadership. Senator Nancy Kassebaum of Kansas, a Republican, introduced the original Senate version of the measure, and Senator Orrin Hatch of Utah later described himself in the Congressional Record as one of the lead Senate sponsors of the statute, which he said passed with overwhelming bipartisan support. The House moved the bill through its committees during 1982, and Waxman pushed it through the full House that year, riding the public awareness that the television episode and Klugman’s testimony had generated. A later account of Hatch’s role describes the final Senate maneuver in dramatic terms: with a likely objector absent from the chamber, Hatch cut his own remarks short and rushed the bill forward by unanimous consent, watching the doors as the parliamentary steps turned, and the measure was called up and approved before any objection could be registered.

The Senate, however, proved harder to move. Hatch, despite his eventual sponsorship, held the bill up in the Senate by insisting that provisions the rare disease advocates considered essential be stripped, including the tax credits for clinical trials of orphan drugs. The objection reflected the pharmaceutical industry’s posture at the time: manufacturers were focused on blockbuster treatments for common diseases and had no interest in developing drugs for rare conditions, while some worried that orphan drug provisions might let new medicines bypass the normal review process. The advocates who had fought for the incentives found their bill stalled by the very market logic they were trying to overcome.

The Stall in the Senate and the Second Episode

Jack Klugman responded to the Senate stall the way he had responded to the original obscurity of the issue: with another episode of television. The eighth season of Quincy, M.E. included “Give Me Your Weak,” which episode listings date to October 27, 1982. In the story, a young man takes his own life after losing access to an experimental orphan drug that had let him live a normal life, and Quincy travels to Washington with two physicians to push for passage of an orphan drug bill on behalf of patients in the same position. The plot turns on the refusal of drug companies to manufacture medicines used by only a small share of the population, and the episode’s cast included Simon Oakland as the fictional Senator Reeves who stood in the way. The producers cast more than five hundred extras, many of them people who actually lived with rare diseases, to fill the scenes of patients demanding action.

The episode aired as the lame-duck session of the 97th Congress approached, and the timing sharpened its effect. Klugman had aimed the story directly at the legislative blockade, dramatizing for a national audience the precise procedural obstruction that the advocates were facing in Washington. Whether any senator changed a vote because of a television drama cannot be measured, but the advocates never doubted the value of the attention. NORD’s anniversary account of the period states plainly that the recognition the episodes brought to the issue, combined with the tireless efforts of parents, patients, and lawmakers, helped push the Orphan Drug Act over the finish line. Television historian Hal Erickson, whose account is cited in the standard reference history of the statute, credits both episodes with helping the measure pass.

The House and Senate resolved their differences in December 1982. Congress.gov records that the House agreed to a Senate amendment with an amendment on December 14, 1982, and NORD records that the Senate approved the final version three days later. The Senate’s version had carried additional provisions unrelated to rare diseases, including measures on home health programs, which the final compromise retained alongside the orphan drug framework. The tax provisions the advocates had fought to keep survived the Senate’s objections and remained in the final text. The bill that emerged was a genuine compromise of the two chambers, carrying both the drug regulation framework the House had shaped and the fiscal provisions that had nearly been stripped away.

Enactment and What the New Law Rewrote

President Ronald Reagan signed the measure on January 4, 1983, and it became Public Law 97-414, recorded in the Statutes at Large at 96 Stat. 2053. The enrolled text bore the formal title “An Act to amend the Federal Food, Drug, and Cosmetic Act to facilitate the development of drugs for rare diseases and conditions, and for other purposes,” as preserved in the Tax Notes archive of the enrolled bill.

The statute rewrote two bodies of federal law at once. It amended the Federal Food, Drug, and Cosmetic Act to create the new framework for drugs intended for rare diseases and conditions, adding provisions for designation of such drugs and for written agency guidance on the investigations needed to support approval. It amended the Internal Revenue Code of 1954 to add a new section providing a tax credit for clinical testing expenses for certain drugs for rare diseases or conditions, the provision originally numbered as section 44H and later renumbered as section 28. The same measure also amended the Public Health Service Act to establish an Orphan Products Board within the Department of Health and Human Services to coordinate the development of orphan drugs and devices.

The law thus attacked the market failure from both sides of the federal apparatus at once: the food and drug statute gained a regulatory pathway built for small patient populations, and the tax code gained a credit aimed at the development costs that had made those populations commercially invisible. Waxman’s summation of the moral case, quoted in NORD’s anniversary account, framed the statute as an answer to an intolerable situation: that people with rare diseases suffer no less and are no less deserving because they are so few.

The origins of the statute remain one of the few cases in American lawmaking in which a television program is plausibly credited with moving legislation across the finish line. The patient advocates had organized, the hearings had been held, and the bill had been drafted before any camera was involved, and none of those steps had produced a law. After the broadcast of March 1981, the testimony of that same month, and the second episode of October 1982, the bill that had stalled became the law that was signed on the fourth day of 1983. The statute’s incentives, its results, and the disputes over how those incentives have been used all belong to later chapters of the story; the beginning belongs to the families, the episode, and the hearing room. The enrolled act opened with a section on the short title and findings, then proceeded to the amendments that gave the new law its shape, and the advocates who had carried the bill through an ad hoc coalition formalized their movement as NORD four months after the signing.

The definition and designation

Every incentive the Orphan Drug Act offers turns on a single gate: the product must be an orphan drug, which means it must be intended for a rare disease or condition as the statute defines that term. The definition is therefore not a preamble or a piece of background. It is the eligibility engine of the whole statute. Congress wrote it twice. The version enacted on January 4, 1983 asked whether the market had abandoned the condition. The version substituted by amendment in 1984 asked instead how many people the condition affects. The difference between the two rewrote how the law actually worked, and understanding both versions, plus the administrative process that applies them, is what separates a working knowledge of the statute from a superficial one.

What did the statute originally mean by a rare disease?

As signed in 1983, the Orphan Drug Act defined a rare disease or condition in purely economic terms. A disease was rare for purposes of the statute if it occurred so infrequently in the United States that there was no reasonable expectation that the cost of developing and making available in the United States a drug for the disease would be recovered from the sales in the United States of that drug. The test asked a question about market neglect, not about head counts. A drug sponsor seeking orphan status had to show the Food and Drug Administration that commercial logic had failed: that the patient population was so small, and the expected return so thin, that no rational company would develop the product without government help.

The economic test was coherent in theory and unworkable in practice. The agency had to make formal determinations about whether each candidate disease satisfied the cost recovery standard, which meant asking sponsors to open their books and prove unprofitability. Aaron Kesselheim, writing in PLOS Medicine on the definition of an orphan, described how the FDA was only beginning to make these determinations about market neglect when Congress stepped in with the 1984 amendment and made the agency’s task dramatically simpler. A contemporary account in Law360 by Charles Andres makes the same point from the industry side: few pharmaceutical companies were willing to provide the financial disclosures the test required. The sponsors who might have sought designation were reluctant to hand regulators the profit projections that would establish their eligibility, and the FDA, in turn, was reluctant to certify commercial hopelessness on thin evidence. The result was a definition that described the right policy idea and a procedure that almost nobody used.

How did the amendment change what counts as a rare disease?

A rare disease or condition is one that affects fewer than 200,000 people in the United States, or one that affects more than 200,000 people but for which there is no reasonable expectation that development costs will be recovered from domestic sales. That two prong formulation, codified at 21 U.S.C. section 360bb, is the statutory definition that replaced the cost recovery test, and it is the definition that has governed eligibility ever since.

Congress made the change through the Health Promotion and Disease Prevention Amendments of 1984, Public Law 98-551, signed on October 30, 1984. Section 4 of that act rewrote section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act by striking the phrase “which occurs so infrequently in the United States that” and inserting in its place “which (A) affects less than 200,000 persons in the United States, or (B) affects more than 200,000 in the United States and for which.” The tail of the original sentence, the clause about no reasonable expectation of cost recovery, remained intact. A report on the legislative history in the Harvard Journal of Law and Technology confirms that prior to this amendment the act provided no numerical ceiling, and that the gap created difficulties for the agencies in determining which diseases were rare. The Congressional Research Service, in its report on patents and marketing exclusivities, states that the effect of the change was to let sponsors avoid making any showing of unprofitability whenever the target population fell under the 200,000 person line.

The number itself was not derived from any epidemiological theory. The National Organization for Rare Disorders, in the report it commissioned from the QuintilesIMS Institute on orphan drugs in the United States, describes the 200,000 threshold as an arbitrary ceiling based on the estimated prevalence of narcolepsy and multiple sclerosis, the two conditions legislators had in mind as the outer boundary of rarity when they chose the figure. Congress picked a round number that captured the conditions everyone agreed were rare, and the number then hardened into the operative legal standard. That arbitrariness is worth keeping in view, because it explains why the definition behaves the way it does: it is a legislative line drawn for administrability, not a medical classification discovered in nature.

The legislative record shows that administrability was exactly the point. When the House took up the measure in October 1984, Representative Waxman explained on the floor that the legislation would change the statutory definition of rare disease or condition to clarify when a drug can be designated by the FDA as an orphan drug, noting that under the amendment a drug for a disease affecting fewer than 200,000 people in the United States would qualify (130 Congressional Record H31,024, daily edition, October 9, 1984). Section 4 of the 1984 act did the work mechanically: it struck the words “which occurs so infrequently in the United States that” from section 526(a)(2) and inserted “which (A) affects less than 200,000 persons in the United States, or (B) affects more than 200,000 in the United States and for which,” leaving the original cost recovery clause in place as the tail of prong (B). A Knowledge Ecology International timeline of the statute’s history reproduces the amendment language verbatim. Note that the enacted text says “less than 200,000 persons,” while most agency guidance and commentary renders the same line as “fewer than 200,000 people”; the two phrasings describe the same ceiling and both appear across the literature, so a reader encountering either form is looking at the same test.

What is the second prong of the definition?

The second prong preserves the original 1983 idea for the population above the line. If a disease affects more than 200,000 people in the United States, a drug for it can still qualify as an orphan drug if the sponsor demonstrates that there is no reasonable expectation that the cost of developing and making available in the United States a drug for the disease will be recovered from sales in the United States. The statute keeps both doors open: one for conditions small enough to be presumed commercially unviable, one for larger conditions where unviability must be shown.

In practice the second prong is the road less traveled, for exactly the reason the original definition failed. To invoke it, a sponsor must submit to the FDA the financial showing that the 1984 amendment excused for the under 200,000 population: development cost estimates, projected sales, and the analysis connecting them. The reluctance that Charles Andres described in Law360, the unwillingness of companies to disclose the figures that would prove a product commercially hopeless, has applied in full to every sponsor choosing the second prong since 1984. The prong exists because Congress did not want the numerical ceiling to exclude, say, a tropical disease with a larger American population that no company would touch for commercial reasons. But sponsors reach for it rarely, because the prevalence prong asks only for an epidemiological head count while the cost recovery prong asks for the company’s internal math, and that calculus has not changed since the 1984 amendment redrew the map.

There is a subtlety in how the second prong is read that matters for later parts of the statute. The clause measures recovery from sales in the United States, not worldwide sales. A drug that could be profitable on global revenue but not on American revenue alone can qualify. Congress drew the line at domestic recovery because the incentives it was offering, the exclusivity, the tax credit, the grants, were instruments of American policy, and the market failure it meant to cure was the abandonment of American patients.

How does a sponsor obtain orphan drug designation?

The designation process sits with the FDA’s Office of Orphan Products Development, the office Congress created to administer this part of the statute. A sponsor submits a request for designation under section 526 of the Federal Food, Drug, and Cosmetic Act, and the implementing regulations at 21 C.F.R. part 316 set out what the request must contain and how the agency evaluates it. The request presents the proposed use of the drug, the evidence that the disease or condition is rare under one of the two prongs, and the scientific rationale, either preclinical or clinical, for expecting the drug to work in that condition. The FDA’s grant FAQs for orphan products describe the core showing as a medically plausible basis for effectiveness plus a population estimate demonstrating that the disease affects fewer than 200,000 people in the United States.

Timing matters, and Congress changed the timing once. As originally enacted, the statute let a sponsor request orphan drug status at any time before FDA marketing approval. The Orphan Drug Amendments of 1988, Public Law 100-290, tightened that window: the designation request must be filed before the sponsor submits its marketing application. The Congressional Research Service reports that the 1988 amendment was aimed at the filing period for designation requests, and the rule is that designation is a pre approval event, not something bolted on after the agency has already begun its review of the marketing application. Sponsors therefore typically seek designation early in development, often before clinical trials are complete, so that the incentives attached to designated status, such as protocol assistance and eligibility for grants, can shape the program that follows.

The regulations also contemplate designation of a drug that is already approved for something else. Section 316.21 of the orphan drug regulations allows a sponsor to request orphan designation of an already approved drug for an unapproved use, without regard to whether the earlier approval was for a rare disease. This is a direct consequence of the per indication structure described below: the designation attaches to the use, and a new use for a rare condition starts the designation analysis over. Once designation is granted, the holder files annual progress reports with the Office of Orphan Products Development under section 316.30 until marketing approval, summarizing the preclinical and clinical studies under way. The reporting obligation keeps the agency informed during the long stretch between designation and the marketing application, and it is one of the concrete ways the designation relationship differs from a mere label.

One technical wrinkle applies to products used in prevention or diagnosis rather than treatment. For vaccines, diagnostic drugs, and preventive drugs, the regulations measure the population as the target population to which the product will be administered, expressed as fewer than 200,000 people annually in the United States, rather than as a point prevalence figure. The orphan designation regulations set out the standard this way because a preventive product’s relevant population is the yearly cohort it would reach, not the total number of people who carry the condition at a given moment. The same 200,000 ceiling applies; only the counting method changes.

Does orphan drug designation mean the drug is approved?

No. This is the most common misunderstanding in discussions of the statute, and the regulations are explicit about the distinction. Orphan drug designation is an administrative status granted during development; it certifies that the proposed use meets the statutory definition of a rare disease or condition and that the sponsor has presented a medically plausible basis for effectiveness. Marketing approval is a separate determination, made under section 505 of the Food, Drug, and Cosmetic Act or section 351 of the Public Health Service Act, that the drug is safe and effective for its indicated use on the full record of clinical evidence. Designation comes from the Office of Orphan Products Development; approval comes from the review divisions after a new drug application or biologics license application survives the standard efficacy and safety review.

The sequence makes the point plain. A sponsor may request designation early in development, years before any marketing application exists, and the designation can remain in place for a decade or more while the clinical program runs. The designation says the agency accepts the rarity showing. It says nothing about whether the drug works. Many designated products fail in trials and are never approved; the designation simply lapses into a historical entry on the agency’s lists. An analysis of the 340B orphan drug exclusion, walking through the three concepts the statute distinguishes, puts it bluntly: designation does not constitute marketing approval, and a drug may carry a designation for years before approval or never reach approval at all. None of the statute’s downstream benefits that depend on approval, above all the seven year exclusivity, are triggered by designation alone. The exclusivity clock starts at approval, and the regulations define orphan drug exclusive approval as running from the date stated in the approval letter. Treating designation as a proxy for approval confuses the eligibility determination with the efficacy determination, and the statute keeps them deliberately apart.

Why is the threshold measured per indication rather than per drug?

The 200,000 figure counts the population for the designated use, not the population for every use of the molecule. The designation is granted for a drug for a rare disease or condition, which is to say for a drug use pair, and the exclusivity that follows attaches to the same drug for the same use or indication. This is why one active ingredient can accumulate several designations over its commercial life, each tied to a different condition, and why a drug first approved for a common condition can later receive an orphan designation for a second, rare use. The Harvard Journal of Law and Technology legislative history notes the 1988 amendment’s allowance of designation requests for already approved drugs seeking a new orphan use, which only makes sense in a framework where the unit of analysis is the indication.

The regulations make the per indication structure explicit through the concept of the orphan subset. Section 316.3 defines an orphan subset of a nonrare disease or condition as a use of the drug in a subset of persons with a disease that is not itself rare, where use outside the subset would be inappropriate because of some property of the drug, for example its toxicity, its mechanism of action, or prior clinical experience. In other words, a condition affecting well over 200,000 people can still yield an orphan designation when the drug is appropriate only for a smaller population carved out by the drug’s own characteristics. The FDA’s guidance on orphan subsets stresses that the carve out must rest on a characteristic of the product that genuinely limits its appropriate use, not on how a sponsor wishes to study or label it, and the grants program FAQs repeat the point that the explanation must convince the agency the product would not be appropriate outside the subset. The prevalence of the designated subset, not the prevalence of the underlying disease, is what is counted against the 200,000 line.

This design choice is the pivot on which the statute’s later controversies turn, and it deserves a neutral description before the critique arrives elsewhere in this article. Per indication designation reflects a clinical reality: drugs are developed and evaluated for specific uses, safety and efficacy are determined indication by indication, and the market failure the statute addresses is the failure to develop treatments for particular patient populations. A per drug rule would have been simpler, but it would have mislabeled the problem. The cost of the per indication approach is that the 200,000 person ceiling gets applied to each use separately, so the aggregate population served by a multi indication molecule can exceed the threshold many times over. Both the flexibility and the consequence flow from the same regulatory sentence in section 316.3: designation is granted for a drug for a rare disease or condition, and the condition, not the molecule, is what the agency measures.

The incentives

The Orphan Drug Act of 1983 did not tell drug companies what to research. It priced the research problem away. A statute that had tried to subsidize rare disease development directly would have had to pick diseases, estimate budgets, and run a grant program large enough to fund full development, none of which Congress was prepared to do in January of 1983. Instead the statute, Public Law 97-414, assembled five instruments that work together and attack the economics from different sides: a period of market exclusivity that guarantees a revenue window, a tax credit that refunds half the cost of clinical testing, a waiver of the fees that admission to the regulatory process charges, direct research grants, and a promise of written guidance from the Food and Drug Administration on how to design the trials. The five share a single trigger. Every one of them flows from the designation of a drug under section 526 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 360bb. Designation is not approval, and approval is not designation; the first is the ticket, the second is the prize, and the statute keeps the two gates separate on purpose.

How does the seven year exclusivity work, and why does the absence of a patent matter?

The core of the statute is the period of exclusive approval set out in section 527, codified at 21 U.S.C. 360cc. When the FDA approves a marketing application, or issues a license, for a drug that was designated for a rare disease or condition, the agency may not for seven years from the date of approval approve another application under section 505 of the food and drug statute or issue another license under section 351 of the Public Health Service Act for the same drug for the same disease or condition, where the other applicant is not the holder of the approved application. The Congressional Research Service, in its product R46679 on the role of patents and regulatory exclusivities in drug pricing, states the effect plainly: the FDA cannot approve another application for the same drug for the same disease or condition for seven years, with limited exceptions.

Two features of that bar deserve attention, because they are the ones most commonly misunderstood. The first is that the seven year period runs from the date of approval, not from the date of designation, and the clock starts only when the FDA actually clears the drug for marketing. A company that wins designation in year one and spends eight years running trials gets no credit for the trial years; the reward is tethered to the moment the drug becomes saleable. The second is that the bar falls on the agency, not on the competitor. The statute does not give the first company a right to sue a rival the way a patent holder can sue an infringer. It forbids the FDA from approving the rival’s paperwork. That distinction matters because it means the exclusivity works even where the rival is ready, willing, and able to manufacture the drug, and even where the underlying chemistry could not support a patent.

The independence from the patent system is the design decision the rest of the world ended up copying. Patents reward invention; the orphan exclusivity rewards commercialization of something that may not be inventive at all. Many orphan drugs were compounds already described in the scientific literature, or older drugs whose chemistry was long past patentability, or substances for which a patent could never have been written because they were products of nature in a form that patent doctrine did not reach. Under an ordinary incentives regime, those drugs had no protection to offer a developer: a patent could not be obtained, and without a patent the first company to pay for the clinical trials would watch competitors free ride on the data the moment approval arrived. The seven year period supplied the missing protection directly, as a regulatory embargo rather than a property right. The sponsor needed no patent, held no patent, and lost nothing when any patents that did exist expired mid-stream, because the embargo did not depend on them.

The statute does not make the embargo absolute. Section 527(b) carves out circumstances in which the FDA may approve a later application during the exclusivity period, including where the holder of the approved application consents and where the holder cannot ensure the availability of sufficient quantities of the drug to meet the needs of persons with the disease or condition. FDA regulations add a further recognized exception: a later drug that is shown to be clinically superior, meaning demonstrably safer, more effective, or making a major contribution to patient care, is not treated as the same drug for exclusivity purposes and may be approved. The exceptions keep the mechanism honest. Consent protects the original sponsor’s ability to license. The supply exception answers the fear that exclusivity would let a company win the market and then starve it. The clinical superiority exception preserves the pressure to improve on existing treatments, so the statute does not freeze a merely adequate therapy in place for seven years.

Measured against the tax code and the fee schedule, exclusivity is the incentive worth the most money to the sponsor and the one that costs the government the least, because it costs the Treasury nothing at all. It is a restriction on competitors, paid for by patients and payers in the form of prices undiluted by competition for seven years, and it is the instrument around which the other four orbit, because it is the one that directly guarantees the revenue window that makes the others worth pursuing.

What does the tax credit for clinical testing cover?

The tax instrument is codified at 26 U.S.C. 45C, under the title “Clinical testing expenses for certain drugs for rare diseases or conditions.” As enacted in the Orphan Drug Act, it was added to the Internal Revenue Code as section 28; it was later renumbered as section 45C, which is why the Treasury regulations that still implement it carry the old number, 1.28-1. The original statute allowed a credit equal to 50 percent of the taxpayer’s qualified clinical testing expenses for the taxable year, where the expenses were incurred in connection with the development of a drug designated under section 526 of the food and drug statute for a rare disease or condition. For a company spending two million dollars on the clinical trials of a designated orphan drug in a qualifying year, the credit erased one million dollars of federal income tax liability, a dollar for every two dollars of trial spending.

The credit was always the most precisely targeted of the five incentives, and the targeting is visible in its definitions. It does not cover preclinical laboratory work in the broad sense, and it does not cover trials for drugs that lack the designation. The expenses that qualify are clinical testing expenses, incurred after designation, before the application for approval is submitted, and in connection with the designated rare disease or condition. A company testing the same molecule for a common condition could not sweep those trial costs into the orphan credit. The credit also sits inside the general business credit framework, which means its value depends on having tax liability to offset, a feature that made it most useful to profitable companies and least useful to the small development stage firms that had no income to shelter.

The 50 percent rate survived from 1983 until the Tax Cuts and Jobs Act of 2017, Public Law 115-97, signed on December 22, 2017, reduced it to 25 percent for taxable years beginning after December 31, 2017. The National Organization for Rare Disorders, the patient advocacy group that had campaigned for the original credit, opposed the reduction and described it as one of the most substantial rollbacks of the incentives for developing orphan therapies; its statement on the proposed changes records that Congress reduced the total amount of the credit for qualifying clinical testing expenses from 50 percent to 25 percent in that legislation. The California Life Sciences policy brief on the credit states the arithmetic the same way, that the 2017 act cut the incentive in half. Investopedia’s explainer of the credit, which cites the Legal Information Institute’s text of section 45C and the FDA’s history of the statute, gives the same two figures: 25 percent after the change, 50 percent before it.

The politics of the cut are worth recording because they show how the credit had become part of the industry’s baseline economics. During the 2017 debate, the House version of the tax bill eliminated the credit outright, while the Senate Finance Committee restored it at a reduced rate after hearing from patient groups, and the conference agreement settled on 25 percent. The result is that the credit refunds one dollar of tax for every four dollars of qualifying trial spending rather than one for every two, still a material subsidy of clinical development, and still tied to the same statutory trigger of designation under section 526.

What application fees does the designation waive?

The third incentive is an exemption from the user fees that the Prescription Drug User Fee Act, known as PDUFA, requires drug sponsors to pay the FDA when they submit applications for approval. The Orphan Drug Act of 1983 predates PDUFA, which Congress first enacted in 1992, so the exemption is not original to the 1983 statute; it is a later layer built on the 1983 designation mechanism. Under section 736(a)(1)(F) of the Federal Food, Drug, and Cosmetic Act, a human drug application for a product designated as a drug for a rare disease or condition under section 526 is not subject to an application fee, unless the application includes an indication for other than a rare disease or condition. The FDA’s guidance on PDUFA waivers, reductions, and refunds explains the procedure: an applicant that qualifies for the orphan exemption does not need to file a separate written waiver request and simply notifies the FDA that it is claiming the exemption on the User Fee Cover Sheet, Form FDA 3397, submitted with the application.

The trigger is designation, and the boundary of the exemption is the designation’s boundary. An application that seeks approval only for the rare disease or condition pays no application fee. An application that adds a common indication loses the exemption for the whole application. That all or nothing design mirrors the tax credit’s logic: the benefit follows the rare use, and a sponsor that wants the benefit for a broad commercial program has to keep the rare program cleanly separate. The exemption also interacts with timing. A sponsor that pays the application fee and receives the orphan designation afterward may request a refund, but the FDA’s guidance requires the refund request no later than 180 calendar days after the fee was due, so designation delayed beyond that window leaves the money spent.

The fee waiver is the smallest of the five incentives in dollar terms, since the application fee is a one time charge measured in millions against development budgets measured in tens of millions, but it is the most symbolically pointed. The user fee program was created to fund the FDA’s review operations from industry payments; exempting orphan applications is the statute’s way of saying that the admission ticket to the regulatory process should not itself be a barrier when the patient population is small. The Congressional Research Service’s legal overview of the act, IF12605, lists the fee waiver alongside the tax credit and grant funding as the financial assistance that designation unlocks.

How do the research grants work?

The fourth incentive is direct public money. Section 529 of the food and drug statute as added by the Orphan Drug Act, codified at 21 U.S.C. 360ee, provides that the Secretary of Health and Human Services may make grants to, and enter into contracts with, public and private entities and individuals to assist in defraying the costs of qualified clinical testing expenses incurred in connection with the development of drugs for rare diseases and conditions, as well as the costs of developing medical devices and medical foods for rare diseases or conditions. The provision defines qualified testing to mean human clinical testing carried out under an investigational exemption for a drug for a rare disease or condition and occurring before the date the approval application is submitted, together with preclinical testing of a designated drug before that same date.

The grants are administered by the Office of Orphan Products Development, the FDA office established in 1982 and tasked with administering the orphan drug provisions. The office’s grant programs fund clinical trials of drugs, biologics, devices, and medical foods for rare diseases, and the FDA’s published guidance for grant applicants describes the mechanics: the study protocol must be submitted to the relevant FDA review division in advance of the grant application deadline, the trial must proceed under an active investigational new drug application or investigational device exemption, and the funding is intended to support trials that address unmet needs in rare conditions. A regulatory slide presentation by the FDA on the orphan drug program states that the Office of Orphan Products Development was established in 1982 and lists grant administration among its core programs alongside designation and exclusivity.

What distinguishes the grants from the other four incentives is that they are discretionary and appropriation dependent. The tax credit is available by statute to any qualifying taxpayer, the exclusivity attaches by operation of law upon approval, and the fee exemption applies automatically to qualifying applications, but grant money exists only to the extent Congress appropriates it in a given fiscal year and the FDA awards it through its competitive process. One legal practice’s overview of the regime notes that early grant funding rarely exceeded a few million dollars a year while later annual levels reached the low tens of millions. The grants were therefore never the engine of the statute; they were the seed money, aimed at academic researchers and small sponsors whose trials might never begin without direct support, while the exclusivity and the credit did the heavy lifting for commercial development.

What is protocol assistance?

The fifth incentive is the least tangible and, to many sponsors, the most practical. Under section 525(a) of the food and drug statute, codified at 21 U.S.C. 360aa, the FDA provides written recommendations concerning the nonclinical laboratory studies and clinical investigations that it considers necessary for the approval of marketing applications for orphan drugs. A sponsor developing a designated drug may request those recommendations before committing to a trial design, and the FDA’s implementing regulations at 21 CFR 316.10 through 316.14 set out the content and format of the request, the circumstances under which the agency may require the results of studies before providing recommendations, the grounds on which it may refuse, and the sponsor’s right to submit additional information within 90 days of a refusal.

The value of the instrument lies in the particular difficulty of rare disease trials. A trial for a common condition can enroll thousands of patients and follow standard designs that every development team knows; a trial for a condition affecting a few thousand people nationwide may be able to enroll only dozens, and the endpoints, the comparator, and the statistical plan may have no precedent. A sponsor that guesses wrong about what the FDA will require can spend years and millions on a trial the agency then deems inadequate. Protocol assistance converts that guess into a written answer. The Federal Register notice that extended the information collection for the orphan drug regulations describes the statutory authority exactly this way: sections 525 through 528 of the act give the FDA authority to provide recommendations on investigations required for approval of marketing applications for orphan drugs, to designate eligible drugs, to set forth the conditions of exclusive approval, and to encourage open protocol treatment use.

The recommendations are guidance, not a contract, and the regulations are candid about their limits. The agency may refuse to provide them where the request is deficient, and the sponsor remains responsible for the trial’s scientific quality. But a sponsor that follows the written recommendations has aligned its development program with the reviewer’s expectations before the first patient is enrolled, which for a rare disease trial, where the patient pool cannot be replenished and the trial cannot easily be repeated, is a form of risk reduction that no tax credit can buy.

Taken together, the five incentives describe a coherent theory of the market failure they were built to fix. The exclusivity guarantees that a market will exist after approval. The tax credit and the grants reduce the cost of getting to approval. The fee waiver removes the toll at the gate. The protocol assistance reduces the chance that the trials will have to be run twice. Each one is triggered by the same designation, each one is bounded by the same definition of rarity, and each one is independent of the patent system, which is why the statute could reach drugs that the patent system had no way to reward.

The incentive table

The five instruments share one trigger, the designation of a drug under section 526 of the Federal Food, Drug, and Cosmetic Act, and each is bounded by the same definition of rarity. The table sets out each incentive with its statutory source, its duration or value, and the strategic use that the record documents. The tax credit row records the change made by the Tax Cuts and Jobs Act of 2017, which cut the rate in half; the exclusivity row is the one whose mechanics sit beside the approval pathway that every drug must still travel.

Incentive	Statutory source	Duration or value	Trigger	Documented strategic use
Seven-year market exclusivity	21 U.S.C. 360cc	Seven years from approval, independent of patents	Approval of a designated orphan drug	Salami slicing: narrow indications carved from common conditions to capture exclusivity per use
Clinical testing tax credit	26 U.S.C. 45C	Fifty percent of qualified expenses, reduced to twenty-five percent for tax years after 2017	Orphan designation under 21 U.S.C. 360bb	Claimed for repurposed mass-market drugs later designated as orphans
Application fee waiver	Orphan provisions of the food and drug statute	One-time exemption from the application fee	Designation before the fee falls due, with refund available within 180 days	Kept separate from broad commercial applications, which lose the exemption
Research grants	Orphan Products grant program	Discretionary, appropriation dependent, from a few million to tens of millions of dollars annually	Competitive agency award	Seed funding for academic and small sponsors whose trials might not begin otherwise
Protocol assistance	Orphan provisions of the food and drug statute	Written agency guidance on trial design	Sponsor request after designation	Aligns rare-disease trials with reviewer expectations before the first patient is enrolled

The results

The Orphan Drug Act was written to fix a market failure: conditions affecting small patient populations attracted almost no commercial drug development, because developing a drug costs roughly the same whether the population numbers a million people or a thousand. The measure of such a statute is what the pipeline did after it passed. The numbers, reported by the Food and Drug Administration and by the analysts who track its orphan drug program, tell a story of scarcity giving way to abundance. In the decade before the statute passed, the agency approved just 10 drugs for rare conditions. Through the end of 2017, the agency had granted nearly 4,500 orphan designations and approved more than 650 orphan drugs. That contrast is the result that matters, and it is what this section documents: the growth curve from 1983 onward, the early approvals that demonstrated the design, the program running at full strength three decades later, and the foreign regimes that copied the American template.

How few treatments existed before the statute

In December 2017, the Food and Drug Administration Commissioner was asked whether the incentives in the 1983 statute were still the right ones. The figures the agency offered in that season were striking for their asymmetry: in the decade before the Orphan Drug Act passed, only 10 industry-supported drugs for rare diseases had been brought to market in the United States, according to the FDA, as reported by Kaiser Health News in December 2017. Since the act, more than 450 individual orphan drugs had been approved. Paul Melmeyer, then the director of federal policy for the National Organization for Rare Disorders, put the same comparison in slightly different terms in a 2016 BioPharma Dive account: only 10 drugs for orphan diseases were approved in the 10 years before the statute’s passage, while since 1983 more than 600 drugs for orphan diseases had been developed. A peer-reviewed paper in the National Bureau of Economic Research volume Innovation Policy and the Economy, in an article titled “The Orphan Drug Act at 35,” used the same decade-length windows for a tighter comparison: just 10 drugs were approved to treat orphan conditions in the decade preceding 1983, while in the decade spanning 2006 to 2015, 274 orphan drugs were approved, a figure attributed there to the researcher Kurt Karst writing in 2018.

The scarcity was structural rather than accidental. Drug development requires clinical trials, regulatory review, and manufacturing capacity that do not scale down when the patient population does. The brief’s own facts and anchors put the point plainly: developing a drug costs the same whether the population is a million people or a thousand, so small populations attracted almost no commercial development. Against that baseline, the first approvals after 1983 were watched closely, because they would show whether a seven year exclusivity grant, detached from any patent, could actually call a market into being.

The early approvals that showed the design working

The first approvals arrived quickly and conspicuously. On October 18, 1985, the Food and Drug Administration approved Genentech’s Protropin, a biosynthetic growth hormone for treating severely growth retarded children, under the brand name somatrem for injection. The company’s announcement noted that the product was the first recombinant human pharmaceutical developed and marketed by a biotechnology company, and only the second recombinant human pharmaceutical approved in the United States, the first being human insulin approved in 1982. Genentech sold Protropin for growth hormone deficiency in children, a population the Human Growth Foundation estimated at 10,000 to 15,000 children in the United States, precisely the kind of small population the statute had been written to serve. The timing mattered for another reason: earlier that year the federal government had halted distribution of the cadaver-derived growth hormone after recipients developed a rare, fatal brain disease, so the recombinant product arrived at a moment of genuine medical need, as Science News reported in October 1985.

In March 1987, the FDA approved zidovudine, sold by Burroughs Wellcome as Retrovir and known as AZT, the first antiretroviral drug cleared in the United States to treat AIDS. The National Cancer Institute’s account records that the compound had been synthesized in 1964 as a cancer candidate, had languished for two decades, and had shown activity against HIV in laboratory work in February 1985. A clinical trial of nearly 300 people was stopped early when the survival advantage became clear, and the agency approved the drug roughly 20 months after the first demonstration of its activity against HIV, an exceptionally fast review. A Time account cited by POZ in March 2017 put the approval date at March 19, 1987. AZT was not a cure, and its initial dosing caused severe side effects, but it demonstrated that the post-1983 legal environment could move a therapy for a newly recognized, terrifying condition to patients with remarkable speed.

A third early approval carried a different significance. In March 1985, the FDA designated Genzyme’s alglucerase, trade name Ceredase, an orphan drug for Gaucher disease, and in April 1991 the agency approved it as the first enzyme replacement therapy. Ceredase was derived from human placental tissue and treated Type 1 Gaucher disease, a genetic enzyme deficiency; before its approval no effective treatment existed for the condition. A 2010 analysis of Genzyme’s business model, published as a case study on the company, reported that clinical trials for Ceredase had begun in 1984, that the FDA designated it an orphan drug in March 1985, and that Genzyme was first allowed to make it available outside the United States in 1990, with FDA marketing approval following in 1991, for a condition afflicting fewer than 10,000 people. Genzyme later replaced it with a recombinant version, imiglucerase, marketed as Cerezyme, approved in May 1994 as an orphan drug for the same disease. Ceredase also illustrated the economics the statute had unleashed: treating a patient population measured in the thousands, the product supported an entirely new company built around rare disease therapies, and its annual cost was reported in 1991 at 20,000 to 60,000 dollars per patient in The Pink Sheet.

The numbers climb through the first quarter century

A peer-reviewed analysis of the FDA’s orphan drug records from 1983 through 2007 gives the shape of the growth curve. On December 31, 2007, the agency listed 1,793 orphan designations granted since 1983, referring to 1,199 products and 889 diseases and conditions, and 322 approvals. The year by year table in that analysis shows the climb: 1 designation in 1983, 40 in 1984, 48 in 1985, and then a steady expansion through the 1990s and 2000s, reaching 121 designations in 2007. Approvals rose more slowly but with the same direction: 2 in 1983, 7 in 1985, 12 in 1989 and 1990, and 13 in 2007, with a mid-period peak of 24 approvals in 1996. The designations were granted to 810 sponsors, including 95 universities, hospitals, public organizations and individual sponsors, and the majority of sponsors held only a single designation, suggesting that the program attracted broad participation rather than concentration among a few firms. Cancer was the largest therapeutic group, accounting for 31.7 percent of all designations in the period, and orphan designations for HIV and AIDS represented 4.9 percent of the total. A later report by the National Organization for Rare Disorders, drawing on FDA data and an analysis by the QuintilesIMS Institute in August 2017, extended the picture through 2015: from 1983 to 2015 there were 1,391 orphan drug designations to treat rare cancers, of which 177 had gained marketing approval, amounting to 36 percent of all orphan drug approvals by 2015, with inborn errors of metabolism, gastrointestinal disorders and neurological conditions making up most of the remaining indications.

The federal grants program attached to the statute contributed its share. In a separate peer-reviewed paper on unintended effects of orphan product designation for rare neurological diseases, the authors reported that 45 of the orphan drugs approved had resulted from the Orphan Grants Program, out of more than 500 studies funded. In the same paper the authors noted the twelvefold increase from 10 approvals in the pre-statute decade to 367 drugs approved in the 28 years after 1983, the count they used in their analysis.

The program running at full strength

By the mid-2010s the program was setting records nearly every year. In 2017 the FDA granted 77 orphan drug approvals and 476 orphan drug designations, shattering the previous records of 49 approvals in 2014 and 355 designation grants in 2015, according to a February 2018 tally by the FDA Law Blog, written by analysts at the law firm Hyman, Phelps and McNamara, which specializes in food and drug regulation. The agency received 526 requests for orphan designation in 2017, a near record slightly below the 2016 record of 582, and was granting requests at a rate of 1.3 per day. The blog attributed the surge partly to the FDA’s Orphan Drug Designation Modernization Plan, which set out to eliminate a backlog of pending designation requests and imposed a 90 day timetable for processing them, and the firm’s director Anne Walsh was quoted by Medical Marketing and Media saying that companies had caught on to the economic and financial benefits the designations provided.

The cumulative totals reported in the same February 2018 account covered the whole history of the program: since 1983 the FDA had granted more than 650 orphan drug approvals, had granted nearly 4,500 orphan drug designations, and had received more than 6,300 orphan drug designation requests. To put those totals in context, orphan drugs had become a substantial fraction of all new drug approvals: 41 percent of the new drugs approved by the FDA in 2016 were orphans, and 39 percent of new drugs approved in 2017, as the Center for Biosimilars reported. The “Orphan Drug Act at 35” analysis added a measure of novelty to the counts: half of all orphan drugs approved in the United States were first in their class, a rate much higher than among non-orphan drugs, citing the work of Miller and Lanthier from 2016. The same analysis offered examples of the novel therapies: ivacaftor, marketed as Kalydeco, offering life-changing relief for certain subtypes of cystic fibrosis, and imiglucerase and eliglustat treating variants of Gaucher disease.

Europe writes its own version

The American demonstration did not stay American. The European Union adopted Regulation 141/2000 on orphan medicinal products, which the European Medicines Agency’s procedural guidance records as adopted on December 16, 1999 and published in the Official Journal of the European Communities on January 22, 2000, with applications for orphan designation accepted from April 28, 2000, once the implementing regulation had entered into force. The regulation set an eligibility threshold of not more than 5 affected persons in 10,000 in the European Union and established the Committee for Orphan Medicinal Products within the European Medicines Agency to examine designation applications.

The European results, measured a decade later, mirrored the American pattern on a smaller scale. An assessment commissioned by the trade associations EuropaBio and the European Biopharmaceutical Enterprises and carried out by the Office of Health Economics, reported by ScienceBusiness in 2010, found that between 2000 and 2004, research and development investment in rare diseases in Europe increased by more than half, and then more than doubled between 2004 and 2008, for total growth in investment of more than 200 percent across the 2000 to 2008 period. The number of marketed treatments for rare diseases rose from 8 to 69 over the same era, and the legislation helped establish new companies in Europe focused on researching new treatments for rare diseases.

Japan built a comparable system even earlier

Japan moved before Europe did. The orphan system was established in Japan by amending the Pharmaceutical Affairs Law in April 1993 and entered into force on October 1 of the same year, as described in a presentation by the Ministry of Health, Labour and Welfare to the European Medicines Agency. The designation criteria required, among other things, that the number of patients who might use the drug be fewer than 50,000 in Japan, that the product address a serious disease for which there was high medical need, and that there be a theoretical rationale for its use with an appropriate development plan.

An analysis marking the twentieth anniversary of the Japanese program, published in the journal of the Japan Society of Hospital Pharmacists, reported that in the 20 years after the program’s establishment the Ministry of Health, Labour and Welfare had designated 300 medicines and 23 medical devices as orphan products, of which 192 medicines and 13 medical devices had been approved. The approvals included several therapies that began their development in Japan: tocilizumab, a humanized antibody against the interleukin-6 receptor discovered by Osaka University and Chugai Pharmaceutical, approved for symptoms associated with Castleman’s disease in 2005; pirfenidone, approved for idiopathic pulmonary fibrosis in 2008; and mogamulizumab, approved for relapsed or refractory CCR4-positive adult T-cell leukemia and lymphoma in 2012. An earlier analysis of the program’s first years found that from its 1993 introduction through the late 1990s, the Ministry had designated 106 orphan drugs, of which 34 had been approved, with 11 compounds receiving the designation more than once and 36 designations representing Japanese original products.

The reputation the results earned

By the statute’s third decade, commentators treated it as the reference case for incentive-based drug legislation. One peer-reviewed paper described the statute as regarded by some as one of the most successful legislative actions in United States history in the public health area. In a December 2017 interview with Kaiser Health News, FDA Commissioner Scott Gottlieb said the law had provided an enormous amount of public health value over the years, and Bernard Munos, a former corporate strategy adviser at Eli Lilly then a senior fellow at FasterCures, said that the statute had clearly delivered. The scholarly evaluation in “The Orphan Drug Act at 35,” published in Innovation Policy and the Economy by the University of Chicago Press, kept the frame the statute’s designers would have recognized: a law whose passage was associated with a vast increase in products for diseases with patient populations below 200,000. The law had, in the FDA’s own reckoning, moved the field from a decade with 10 approvals to a single year, 2017, with 77.

The same literature kept a necessary caution alongside the praise. The paper on unintended effects of orphan designation for rare neurological diseases noted that the increase might not have come purely from the statute, pointing to the major increase in public and private investment in pharmaceutical research and development over the same period, major advances in science and technology, other legislation that lengthened patent terms and market exclusivity, changes to FDA review procedures, and the growth of patient advocacy groups. The tension is the one the brief names: thousands of designations and hundreds of approvals for conditions that previously had no treatments are real, and they are consequences of the same design choice that produced the statute’s later criticisms. Both belong to the results.

The gaming critique

The Orphan Drug Act worked by changing the arithmetic of drug development. Where a disease affected too few people to repay the cost of developing a treatment, Congress offered a bundle of inducements that made the investment rational. That design choice, applied indication by indication, also created the opening that government auditors and academic researchers documented over the following three decades. The same feature of the law that rewards a developer for taking on a disease no one else will touch rewards a developer for carving a narrow slice out of a disease everyone already treats. Both results flow from the same mechanism, and the record from 1983 through the first half of 2018 presents them as parallel facts rather than as rival stories.

Why does exclusivity attach to the use rather than the drug itself?

The seven year market exclusivity at the center of the statute bars the Food and Drug Administration from approving the same drug for the same orphan designated use for seven years after approval. That phrasing contains the mechanism. The protection covers the pairing of a molecule with an indication, not the molecule in the abstract. A different sponsor may market the same compound for a different use, and a different compound may be marketed for the same orphan use, without touching the exclusivity. Health Affairs, in a policy brief published July 21, 2017, stated the consequence directly: designation is granted for a use, so one product may accumulate multiple orphan designations across different rare diseases and may also hold approvals for non orphan uses.

The counting rule that decides eligibility works the same way. The statute’s 200,000 patient threshold counts the population for the proposed use. A sponsor that defines its proposed use narrowly counts a narrow population. The original 1983 text never measured the size of the market the product would ultimately serve. So the developer that sets out to treat a rare disease from the start and the developer that identifies a narrow population inside a common disease both arrive at the same administrative door with the same qualifying number.

The statute contains a second path to eligibility that almost no one uses, and its disuse sharpens the point. A sponsor may seek designation for a disease affecting more than 200,000 people by demonstrating that there is no reasonable expectation of recovering development costs from domestic sales, but Health Affairs noted in its 2017 brief that this approach has been used only a handful of times. The numerical path, the count of patients for the proposed use, does nearly all the work. Kaiser Health News, in its January 2017 investigation, described the consequence in plain terms: manufacturers can return to the Food and Drug Administration with the same drug again and again, each time testing the drug against a new rare disease, with each approval bringing its own set of incentives and its own seven year shield.

Under this structure, each approval can carry its own period of protection. A product approved once for an orphan use receives seven years of exclusivity for that use. A second approval for a different orphan use carries its own protection for that use. The exclusivity was conceived as statutory protection independent of the patent system, protection for products that lacked patents or whose patents could not be enforced, as the Health Affairs brief noted. Once the exclusivity became valuable in its own right, the incentive ran in two directions at once: toward diseases with no treatments, and toward additional uses of drugs that already had them.

What is salami slicing?

The term comes from the practice it names. Health Affairs defined it in the same 2017 brief: disputes arise over whether a proposed patient population has been defined arbitrarily to create an orphan indication, and the metaphor describes a sponsor that intends to market a medicine for a large patient population, for example people with lung cancer, but seeks orphan designations first for one slice of the market, stage 4 lung cancer, then for another, stage 3. The slice qualifies because the count is taken at the slice level. The whole never has to.

The agency pushed back on the thinnest versions of this move. In June 2013 the Food and Drug Administration issued a final rule on orphan drug regulations that created a formal concept called the orphan subset, setting the conditions under which a subset of a non rare disease could support a designation. The rule addressed a phrase that had been doing too much work: sponsors had read the agency’s earlier “medically plausible” language to mean any medically recognizable or clinically distinguishable subset of patients, which, in the agency’s own words in the Federal Register notice, could result in artificially narrow subsets for the purpose of orphan drug designation. The 2013 rule required instead that the properties of the drug be shown to preclude its use outside the claimed subset. A sponsor could no longer defend a slice merely by pointing to a distinction a clinician would recognize; it had to show why the drug could not be used for the rest of the disease.

Genomic medicine made the question harder even as the rule made the standard stricter. As researchers learned to define cancers and other disorders by the genetic markers of a tumor rather than by the organ where it appears, the boundary between a genuine rare disease and a rare slice of a common one grew harder to draw. A therapy designed to act on a specific mutation will, by its mechanism, treat only the patients who carry that mutation. When that mutation appears in a small fraction of patients with a common cancer, the designated population falls under the threshold while the underlying disease does not. The Government Accountability Office, in its November 2017 report on the drug industry, acknowledged that many new oncology drugs are approved for treatment of tumors with specific genetic markers, and the report noted that such products can face a less elastic demand curve that facilitates higher pricing. Whether a biomarker defined population is a discovery or a strategy depends on facts no filing can fully capture, and the literature has treated that ambiguity as structural rather than as a matter of individual good faith.

Academic researchers described the pattern early. In 1999 Gary A. Pulsinelli, writing in the Santa Clara High Technology Law Journal, warned that a developer could acquire multiple approvals for the same drug for what were essentially facets of the same disease and obtain market exclusivity for a medicine that was not really an orphan, calling the result an abuse of the principles of the act. The warning predated the genomics era, which suggests that the vulnerability lay in the design of the counting rule rather than in any particular technology.

What did the investigations find?

The most detailed accounting came from a six month Kaiser Health News investigation published in January 2017. Two reporters analyzed several Food and Drug Administration databases and found that about a third of orphan approvals granted since the program began were either for repurposed mass market drugs or for drugs that received multiple orphan approvals. More than 70 medicines first approved for mass market use were later approved as orphans, with their sponsors receiving a fresh set of incentives and seven years of exclusive rights for each rare disease indication. More than 80 other products won approval for more than one rare disease, each additional approval carrying another batch of incentives. The investigation also found that the share of new medicines approved with orphan status had grown sharply: in 2015, 21 orphan drugs won approval, accounting for 47 percent of all new medicines, up from 29 percent in 2010, and in 2016 nine more won approval, 40 percent of the total.

The agency’s response was candor rather than denial. Gayatri Rao, director of the Food and Drug Administration’s Office of Orphan Products Development, told the reporters after reviewing their findings for two weeks that she appreciated the work and that the office would study how often sponsors were repurposing a drug for a new rare disease, language she rendered as taking multiple bites of the apple. Rao added that she could consider a regulatory change. She also offered the counterweight that the statute’s authors had intended: repurposing has scientific and patient benefits, since a therapy approved for one malignancy can be tested and approved for others.

The academic critique arrived from a different direction. In a commentary published online November 19, 2015 in the American Journal of Clinical Oncology, Martin A. Makary and colleagues at the Johns Hopkins University School of Medicine argued that developers were claiming orphan status for products that ended up marketed for more common conditions. Makary described the tactic as slicing and dicing indications so that products qualified for lucrative orphan benefits, and he named the mechanism salami slicing: identifying small patient populations to gain additional approvals, each carrying government benefits and subsidies, with prices rising because each new approval brought seven years without competition for a new set of patients. His commentary also acknowledged what the statute had accomplished, crediting it with sparking life saving therapies for cystic fibrosis, muscular dystrophies, and certain pediatric cancers, before arguing that the law had invited abuse alongside its successes.

Congress noticed. In 2017, at the request of Senators Orrin Hatch, Chuck Grassley, and Tom Cotton, the Government Accountability Office accepted an investigation of the orphan drug program, with the senators asking for analysis that could support legislation to preserve the intent of the law. The request itself, and the language the senators used about potential abuse of the program, signaled that the critique had moved from journals and newsrooms into the committee rooms where the statute had been written.

Why do orphan designated products carry such high prices?

The pricing record is where the critique draws its strongest numbers, and the numbers come from industry analysts rather than from the law’s critics. EvaluatePharma, the commercial intelligence firm whose orphan drug reports the field treats as standard references, projected in its May 2018 Orphan Drug Report that orphan drug sales would grow at a compound annual rate of 11.3 percent between 2018 and 2024, roughly double the rate for non orphan drugs, approaching 22 percent of global prescription drug sales by that year. The same report put the mean 2017 orphan drug cost to patients in the United States at around 150,000 dollars. The firm’s 2017 report had put the average annual cost per patient for the top 100 orphan drugs in the United States at 140,443 dollars in 2016.

The Government Accountability Office added its own finding in November 2017. In GAO-18-40, its report on the drug industry’s profits, research spending, and dealmaking, the office wrote that orphan drugs can often garner high prices compared with non orphan drugs, citing an industry report, and it linked part of the pattern to precision medicine: new oncology products approved for tumors with specific genetic markers can face less elastic demand, which facilitates higher pricing.

Health Affairs, in its July 2017 policy brief, described the mechanism that turns exclusivity into pricing power without attributing motives to any party. The brief noted that drugs approved exclusively for rare diseases often carry prices of hundreds of thousands of dollars per patient per year, and that sponsors explain those prices as the return required on development costs spread across few patients. It also noted the cases that strain that explanation: a number of products approved solely for orphan indications generate annual sales above one billion dollars, the conventional marker of a blockbuster built for common diseases, even though such products were a small minority among the more than 500 orphan approvals the brief counted. The brief drew the inference as a question about the program’s premise rather than as an accusation: when a product built for a population under 200,000 sells like a product built for millions, the premise that no viable commercial market exists for rare disease treatments becomes harder to sustain. Kaiser Health News, citing EvaluatePharma’s sales rankings in its January 2017 investigation, reported that orphan drugs accounted for seven of the 10 top selling drugs of any kind, ranked by annual sales, a figure that placed products developed under a rare disease statute at the summit of the industry’s commercial rankings.

Can the program’s success and its critics both be right?

The complication at the center of this section is that they can, and the record supports both readings at once. By the measure of its own founding purpose, the statute succeeded beyond what its authors predicted. Kaiser Health News, the same investigation that documented the repurposing pattern, reported that more than 200 companies had brought almost 450 orphan drugs to market since the law took effect, and it wrote that no one disputes that orphan drugs have helped or saved hundreds of thousands of patients with debilitating or fatal rare diseases. Health Affairs counted more than 3,500 designations granted and more than 500 drugs approved since 1983, with designation requests reaching a record 440 in fiscal year 2015, double the number five years earlier. The Health Affairs brief added that the market exclusivity approach had been imitated in other incentive programs enacted over the following three decades, a judgment the field shares with the European and Japanese regimes the brief’s companion sections describe.

The critics of the subdivision practice do not dispute those counts. Makary’s 2015 commentary credited the statute with life saving therapies for named rare disorders. Former Representative Henry Waxman, a principal author of the 1983 law, told Kaiser Health News that the act had been a great success because many people with diseases affecting very few people then had drugs available, while adding that it had in some ways been turned on its head when it became the basis for extracting more money than an open competitive market would allow. Anne Pritchett, vice president for policy and research at the industry group PhRMA, made the case for the incentives themselves in the same investigation, pointing to the long, costly, and risky character of development and to therapies such as the cystic fibrosis treatment that took 25 years to develop, and warning against anything that would undermine the incentives.

The two readings describe the same instrument from opposite ends. Exclusivity that attaches to the indication rewards the developer who tests an existing therapy against a rare disease the market ignored, and it rewards the developer who tests an existing therapy against a narrow slice of a common one. The seven year protection that made an unprofitable project viable also made each additional use valuable, and the grants and fee relief that lowered the cost of studying a rare condition lowered the cost of studying a rare slice. The statute never asked whether the patient population was rare because the disease was rare or because the indication was drawn narrowly; it asked only for the count. That single design decision produced hundreds of treatments for conditions that previously had none and produced the subdivision practice in the same motion, and the record from 1983 through the first half of 2018 gives neither result without the other.

Closing assessment

The Orphan Drug Act demonstrated that a government can create a viable market for an unprofitable product by granting a period of protection detached from the patent system entirely. That demonstration is the statute’s namable claim: exclusivity without a patent. Before 1983, no American law had tried to manufacture a market for drugs that the patent system could not reward, because patents reward invention and the orphan problem was never a shortage of invention. It was a shortage of buyers. The statute answered the buyer shortage with a revenue window that patents had no way to provide, and the answer worked well enough to be copied. Regulators in Europe and Japan built their own orphan regimes on the American template, and American law extended the exclusivity model a year later when Congress enacted the Hatch-Waxman framework, which built its own protection periods into the generic drug system. The two statutes together define how American pharmaceutical law manufactures protection and competition side by side.

Both halves of the record are consequences of the same design choice. Thousands of designations and hundreds of approvals for conditions that previously had no treatments are real. The subdivision practice is documented. One is not the truth while the other is spin. The statute attached its benefits to the indication because a definition measured per molecule would have left follow-on uses outside the scheme, and per-indication attachment is what made the incentives administrable across thousands of distinct conditions. The same attachment is what let sponsors define narrow subsets of common conditions and claim incentives designed for rare ones. The prices that orphan-designated products command are the unresolved cost of that design, and the investigations that quantified the repurposing and the multiple approvals are the price of the precision.

That bargain is the thesis this profile carries for the series. The Orphan Drug Act sits in the sequence of American health legislation as the moment when Congress stopped treating drug development as a purely private investment decision and began pricing the market failure out of existence. The law’s authors bought both halves with one purchase: they accepted that an incentive precisely targeted at a market failure would be pursued by everyone who could qualify, including those the failure does not describe. The thousands of rescued pipelines and the documented gaming belong on the same page because they were written by the same hand, the hand that wrote exclusivity to the use rather than to the drug.

Readers working through the statute can use the VaultBook legislation study notebook to organize the five incentives, the two prongs of the rarity definition, and the designation and approval counts by period.

Frequently asked questions

Q: What does the Orphan Drug Act provide?

The statute provides five incentives, all triggered by a single orphan designation: seven years of market exclusivity running from approval and independent of any patent, a tax credit for qualifying clinical testing expenses, a waiver of application fees for designated products, research grants awarded through the agency’s orphan products program, and written protocol assistance on trial design.

Every benefit flows from designation under section 526 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 360bb. Designation is not approval, and approval is not designation. The first is the ticket that unlocks the incentives; the second is the prize that requires the full showing of safety and efficacy. The statute keeps the two gates separate on purpose, so a sponsor can secure the incentives early and then spend them on the trials that lead to approval.

Q: What counts as a rare disease under the Orphan Drug Act?

A rare disease or condition is one affecting fewer than 200,000 persons in the United States, or one for which there is no reasonable expectation that the costs of development and distribution will be recovered from sales in the United States. The numerical threshold, added by amendment in 1984, is the prong that does almost all of the work.

The second prong measures recovery from domestic sales only, not worldwide revenue, because the incentives are instruments of American policy aimed at the abandonment of American patients. The threshold is measured per indication rather than per drug, which is why one medicine can hold several orphan designations for different uses. That per-indication measurement is also the opening that made the subdivision strategy possible.

Q: How long is Orphan Drug Act exclusivity?

Seven years from the date of approval. During that period the Food and Drug Administration may not approve another application for the same drug for the same use or indication, even if the competing sponsor has run its own trials and could otherwise satisfy the approval standard.

The exclusivity is codified at 21 U.S.C. 360cc and operates independently of the patent system. A drug with no patent protection at all still receives the full seven years, and a drug whose patents expire during the period keeps the exclusivity to its end. That independence is the point of the design: it reaches compounds the patent system has no way to reward, including old molecules and drugs whose patent life has already run.

Q: Did a television episode help pass the Orphan Drug Act?

Yes. The drama Quincy, M.E. aired “Seldom Silent, Never Heard” on March 4, 1981, in which the coroner’s investigation of a teenager’s death with Tourette syndrome turns on the refusal of drug companies to develop treatments for disorders too rare to reward the investment. The legislative history credits the broadcast with generating the public pressure that moved the bill.

The episode’s writer-producer, Maurice Klugman, was himself living with a rare cancer. After the broadcast, letters arrived from families across the country who had believed they were alone. His brother Jack Klugman, the show’s star, testified before Representative Henry Waxman’s House subcommittee that same month, and a second episode, “Give Me Your Weak,” aired October 27, 1982, aimed at the Senate stall. The bill was signed on January 4, 1983.

Q: How many orphan drugs existed before the Orphan Drug Act?

About ten. In the decade before 1983, industry brought only ten new treatments to market for diseases that fall within the rare-disease definition, according to the National Organization for Rare Disorders. Representative Waxman recalled that before 1980, drug companies did virtually no research on rare-disease cures because the populations were too small to offer an adequate return.

That scarcity is the baseline against which the statute’s results are measured. Through the end of 2017, the agency had granted nearly 4,500 orphan designations and approved more than 650 orphan drugs. The contrast between ten treatments in a decade and hundreds of approvals in three decades is the central result the statute’s supporters cite.

Q: What is salami slicing under the Orphan Drug Act?

Salami slicing is the practice of defining narrow subsets of common conditions to qualify for orphan incentives designed for rare ones. Because exclusivity attaches to the designated indication rather than the molecule, a sponsor can carve a slice from a widespread disease, obtain designation and exclusivity for that slice, and then market into a much larger population.

The term captures the vulnerability in the counting rule rather than any particular technology. Government auditors and academic researchers documented the practice, and one analyst warned before the genomics era that the statute let sponsors subdivide a disease and obtain market exclusivity for a medicine that was not really an orphan. The subdivision critique is the statute’s most durable controversy.

Q: Why are Orphan Drug Act medicines so expensive?

Two structural reasons. First, the fixed costs of development are spread across very small patient populations, so the per-patient price needed to recover the investment is high even before any profit. Second, the seven-year exclusivity bars competing versions of the same drug for the same use, giving the sponsor a protected market in which to set that price.

The result is that orphan-designated products command among the highest prices in medicine. The pricing question is reported factually because it is emotionally and politically charged: the development incentive and the pricing concern deserve equal care, and neither the manufacturers nor the patients are characterized. High prices are a documented consequence of the design, not proof that the design failed.

Q: What tax credit does the Orphan Drug Act give?

A credit under 26 U.S.C. 45C for qualified clinical testing expenses incurred for a drug designated under section 526 for a rare disease or condition. As enacted, the credit equaled 50 percent of the qualifying expenses, so a company spending two million dollars on eligible trials erased one million dollars of federal income tax liability.

The 50 percent rate survived until the Tax Cuts and Jobs Act of 2017 reduced it to 25 percent for taxable years beginning after December 31, 2017. During the 2017 debate the House version eliminated the credit outright, the Senate Finance Committee restored it at the reduced rate after hearing from patient groups, and the conference agreement settled on 25 percent. The patient advocacy community opposed the cut as one of the most substantial rollbacks of the incentives.

Q: How does orphan drug designation differ from drug approval?

Designation is the administrative finding that a drug is intended for a rare disease or condition, made by the Food and Drug Administration’s Office of Orphan Products Development on the sponsor’s request with prevalence or cost-recovery data. Approval is the separate determination, after full clinical trials, that the drug is safe and effective for its intended use.

Designation unlocks the five incentives. Approval triggers the seven-year exclusivity. A designated product that never completes its trials receives the grants, the credit, and the guidance but never the exclusivity, while an approved product that was never designated receives no orphan benefits at all. The common error is treating designation as a promise of approval; the statute treats it as a promise of support on the way there.

Q: Why does orphan exclusivity not require a patent?

Because the statute grants it by operation of law. Section 360cc provides that no approval of another application for the same drug for the same use or indication may be made effective during the seven-year period, and that bar attaches when the designated drug is approved, regardless of whether any patent exists or remains in force.

The independence from patents is the statute’s central innovation. The patent system rewards invention, but the orphan problem was never a shortage of invention; it was a shortage of buyers. By detaching protection from patents, Congress could reward development of compounds the patent system had no way to reach: old molecules, drugs whose patents had expired, and products whose commercial prospects were too thin for patent-driven investment to bother.

Q: What did the nineteen eighty-four amendment change about the rare disease definition?

It replaced the original economic test with the numerical prevalence threshold. As enacted in January 1983, the statute asked whether there was no reasonable expectation that development costs would be recovered from domestic sales. The 1984 amendment, Public Law 98-551, substituted a headcount: a rare disease is one affecting fewer than 200,000 persons in the United States.

The change rewrote how the law actually worked. The economic test required the agency to judge each sponsor’s cost projections; the numerical threshold made eligibility administrable with population data. The original cost-recovery language survived as the definition’s second prong, so a condition above the headcount can still qualify if the economics fail, but the threshold does nearly all of the gatekeeping.

Q: How did the bill become law despite stalling in the Senate?

The House moved first. Representative Henry Waxman introduced H.R. 5238 on December 15, 1981, and pushed it through his committees and the full House during 1982, riding the public awareness the Quincy episode and Jack Klugman’s testimony had generated. In the Senate, the bill stalled when provisions the advocates considered essential, including the clinical trial tax credits, drew objections.

The second Quincy episode, “Give Me Your Weak,” aired October 27, 1982, dramatizing the legislative blockade for a national audience as the lame-duck session approached. Senator Orrin Hatch, who described himself as a lead Senate sponsor, rushed the bill through by unanimous consent with a likely objector absent. The enrolled act was signed on January 4, 1983, and the advocates formalized their movement as the National Organization for Rare Disorders four months later.

Q: What did the Kaiser investigation find about orphan drug approvals?

A six-month Kaiser Health News investigation, published in January 2017, found that about a third of orphan approvals were for repurposed mass-market drugs or drugs with multiple orphan approvals. More than 70 medicines first approved for mass-market use were later approved as orphans, and more than 80 products won approval for more than one rare disease.

The investigation also found the orphan share of new medicines growing sharply: 21 orphan drugs won approval in 2015, accounting for 47 percent of all new medicines, and nine more in 2016, or 40 percent. Gayatri Rao, director of the agency’s Office of Orphan Products Development, responded with candor, saying the office would study how often sponsors were taking multiple bites of the apple.

Q: How did Europe and Japan respond to the Orphan Drug Act?

Both copied the American template. Japan built a comparable orphan drug system, and Europe adopted its own orphan regulation in 2000, each offering designation-linked incentives modeled on the 1983 statute’s approach of manufacturing a market through exclusivity and financial support rather than through direct subsidy.

The international copying is the statute’s most cited vindication. A law written for the American market failure became the reference design for orphan drug policy worldwide, which is why the statute is routinely described as the model regime. The copying also exported the design’s tensions: wherever exclusivity attaches per indication, the subdivision strategy that American auditors documented has a parallel opening.

Q: What is protocol assistance under the Orphan Drug Act?

Written agency recommendations on the investigations needed to support approval of a designated orphan drug, provided by the Food and Drug Administration at the sponsor’s request. The assistance covers how to design the clinical trials, including the endpoints and the patient population, before the first patient is enrolled.

The recommendations are guidance, not a contract, and the agency may refuse deficient requests while the sponsor remains responsible for the trial’s scientific quality. For a rare-disease trial, where the patient pool cannot be replenished and the trial cannot easily be repeated, aligning the program with reviewer expectations in advance is a form of risk reduction that no tax credit can buy. Of the five incentives, it is the least financial and the most operational.

Q: Which application fees does orphan designation waive?

The fee for an application seeking approval only for the rare disease or condition. The exemption is all or nothing: adding a common indication loses the waiver for the whole application, mirroring the tax credit’s logic that the benefit follows the rare use and that a broad commercial program must stay separate from the rare one.

Timing matters. A sponsor that pays the fee and receives the designation afterward may request a refund, but the agency’s guidance requires the request no later than 180 calendar days after the fee was due, so designation delayed beyond that window leaves the money spent. The waiver is the smallest incentive in dollar terms against development budgets, but the most symbolically pointed.

Q: How do the orphan drug research grants work?

They are discretionary and appropriation dependent, awarded competitively by the Food and Drug Administration’s orphan products program. Unlike the tax credit, which is available by statute to any qualifying taxpayer, and the exclusivity, which attaches by operation of law upon approval, grant money exists only to the extent Congress appropriates it in a given fiscal year.

Early grant funding rarely exceeded a few million dollars a year, while later annual levels reached the low tens of millions. The grants were therefore never the engine of the statute; they were the seed money, aimed at academic researchers and small sponsors whose trials might never begin without direct support, while the exclusivity and the tax credit did the heavy lifting for commercial development.

Q: Why is the rarity threshold measured per indication rather than per drug?

Because designation and exclusivity attach to the use, not the molecule. The statute defines a rare disease or condition, and a drug is designated for that condition; the 200,000-person threshold therefore tests the population of the indication, and one medicine can accumulate several designations and several exclusivities for different uses.

The per-indication measurement is the feature that makes the incentives administrable across follow-on uses, and it is simultaneously the opening that made salami slicing possible. The recurring error is assuming the threshold applies per drug, as though a medicine for a common condition could never hold an orphan designation; the statute’s answer is that the designation follows the slice, and the exclusivity protects the slice.

Q: Can one drug hold several orphan exclusivities?

Yes. Each designated indication that reaches approval can carry its own seven-year period of market exclusivity, so a single molecule can accumulate overlapping protections as sponsors win approval for successive rare uses. The Kaiser Health News investigation found more than 80 products that won approval for more than one rare disease, each additional approval carrying another batch of incentives.

The agency’s own orphan products director acknowledged the pattern, describing sponsors as taking multiple bites of the apple and saying she could consider a regulatory change. The statute’s authors intended repurposing to have scientific and patient benefits, since a therapy approved for one condition can be tested for others; the critics’ point is that each bite renews the commercial protection.

Q: What makes the Orphan Drug Act a model statute?

It proved that a government can create a viable market for an unprofitable product by granting protection detached from the patent system entirely, and that demonstration has been copied worldwide and exploited domestically in equal measure. No earlier American law had manufactured a drug market this way, and regulators in Europe and Japan built their orphan regimes on the template.

The statute is taught as incentive design and as the cost of precise targeting in the same lesson. The thousands of designations and hundreds of approvals for previously untreatable conditions are real, the subdivision practice is documented, and both flow from the same choice to attach the benefits to the indication. A model statute, in this telling, is not a flawless one; it is one whose mechanism is clear enough to copy and whose trade-offs are legible enough to debate.